Suicide and self-harm following prescription of SSRIs and other antidepressants: Confounding by indication

British Journal of Clinical Pharmacology

Volumn 60, Issue 5, 2005, Pages 519-525

  Didham, Rebecca C ^a   McConnell, Doug W ^a   Blair, Hayden J ^a   Reith, David M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DOSULEPIN; DOXEPIN; FLUOXETINE; IMIPRAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOMUTILATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPRESSION; DRUG INDICATION; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SUICIDE;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; SELF-INJURIOUS BEHAVIOR; SEROTONIN UPTAKE INHIBITORS; SUICIDE;

EID: 27444441212     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.02480.x     Document Type: Article

References (22)

1. Waechter F. Paroxetine must not be given to patients under 18. BMJ 2003; 326 (7402): 1282.
2. Reith D, Fountain J, Tilyard M, McDowell R. Antidepressant poisoning deaths in New Zealand for 2001. NZ Med J 2003; 116 (1184) (U646): 1-7.
3. GlaxoSmithKline Inc. Paroxetine and pediatric and adolescent clinical trial data. http://www.gsk.com/media/paroxetine.htm. 24th November 2004.
4. Beasley CM, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH, Heiligenstein JH, Thompson VL, Murphy DJ, Masica DN. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ 1991; 303 (6804): 1058-9.
5. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310 (6974): 215-8.
6. Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160 (4): 790-2.
7. Jick H, Kaye J, Jick S. Antidepressants and the risk of suicidal behaviours. JAMA 2004; 292 (3): 338-42.
8. Fergusson D, Doucette S, Glass KC, Shapiro S, Healy D, Hebert P, Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005; 330 (7488): 396.
9. Teicher MH, Glod CA, Cole JO. Antidepressant drugs and the emergence of suicidal tendencies. Drug Saf 1993; 8 (3): 186-212.
10. Szanto K, Mulsant B, Houck P, Dew M, Reynolds C. Occurrence and course of suicidality during short-term treatment of late-life depression. Arch Gen Psychiatry 2003; 60 (6): 610-7.
11. Stata Corporation. Intercooled STATA 8.0 for Windows 8.0. College Station: Stata Corporation, 2003.
12. Grimes D, Schulz K. Bias and causal associations in observational research. Lancet 2002; 359: 248-52.
13. Keitner G, Posternak M, Ryan C. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003; 64 (9): 1091-3.
14. Levi F, La Vecchia C, Lucchini F, Negri E, Saxena S, Maulik P, Saraceno B. Trends in mortality from suicide, 1965-99. Acta Psychiatr Scand 2003; 108 (5): 341-9.
15. Carter G, Reith DM, Whyte IM, McPherson M. Repeat self-poisoning patients: increasing severity of self-harm is predictive of subsequent suicide. Br J Psychiatry 2005; 186: 253-7.
16. Ministry of Health. Suicide Facts: Provisional 2000 Statistics (all ages). Wellington: Ministry of Health, 2003.
17. Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K, Gardner D, Faulding J, Madeley R. Deliberate self-harm and antidepressant drugs - Investigation of a possible link. Br J Psychiatry 2000; 177: 551-6.
18. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, Evans S, Gunnell D. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330 (7488): 389.
19. SmithKline Beecham. A double-blind, multicentre placebo controlled study of paroxetine in adolescents with unipolar major depression. SB Document number BRL-029060/RSD-100TNP/2; 1998.
20. SmithKline Beecham. A randomised, multicenter, 8-week, double-blind, placebo-controlled flexible dose study to evaluate the efficacy and safety of paroxetine in children and adolescents with major depressive disorder. SB Document number: BRL-029060/RSD-101COC/1; 2001.
21. Tilyard M, Dovey S, Spears G. Biases in estimates from the RNZCGP computer research group. NZ Med J 1995; 108: 118-21.
22. Hall J, Tomlin A, Martin I, Tilyard M. A general practice minimum data set for New Zealand. NZ Med J 2002; 115 (1163): 1-7.